French proposals will draw a mixed reaction from industry
This article was originally published in Clinica
Proposed changes to the reimbursement and pricing process for medical devices in France would have both positive and negative effects for industry, say local experts.
You may also be interested in...
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.